Brief: Matinas Biopharma - remains in discussions with Biontech for option to license lnc platform for MRNA on an exclusive basis

Matinas BioPharma Holdings

11/08/2022 11:31

Aug 11 (Reuters) - Matinas BioPharma Holdings Inc  MTNB.A :
    * MATINAS BIOPHARMA - REMAINS IN DISCUSSIONS WITH BIONTECH
FOR
OPTION TO LICENSE LNC PLATFORM FOR MRNA ON AN EXCLUSIVE BASIS
    * MATINAS BIOPHARMA - BELIEVES CASH ON HAND IS SUFFICIENT TO
FUND
PLANNED OPERATIONS THROUGH 2023
    * MATINAS BIOPHARMA HOLDINGS INC QTRLY  NET LOSS OF $0.03
PER
SHARE (BASIC AND DILUTED)


Further company coverage:  MTNB.A